Oral semaglutide lowered hemoglobin A1c more than empagliflozin in a recently published open-label, head-to-head comparison of the type 2 diabetes drugs.

The findings from the PIONEER-2 trial were published online in Diabetes Care. At 26 weeks, oral semaglutide reduced A1c, but not body weight, significantly more than empagliflozin, but by 52 weeks, body weight was also reduced significantly more with the GLP-1 agonist, at least by one calculation.